Equities
Health CarePharmaceuticals and Biotechnology
  • Price (EUR)110.80
  • Today's Change1.60 / 1.47%
  • Shares traded10.15k
  • 1 Year change+7.57%
  • Beta0.5724
Data delayed at least 15 minutes, as of Mar 28 2024 11:21 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Ipsen SA is a France-based biopharmaceutical group specialized in specialty care. The Company operates globally through two segments: Specialty Care and Consumer Healthcare. In Specialty Care, the Company is focused on various therapeutic areas, including oncology, neurosciences and rare diseases. Its oncology portfolio includes Somatuline, Decapeptyl, Cabometyx and Onivyde. Its neuroscience portfolio includes Dysport, and in rare diseases key products are NutropinAq and Increlex. Its primary care portfolio includes Smecta, Forlax, Fortrans, Eziclen, and Tanakan. In oncology Ipsen focuses on a number of disease areas, which include neuroendocrine tumors, renal cell carcinoma, hepatocellular carcinoma and pancreatic cancer. In addition, the Company has specialism in neurotoxin research and operates three research and development centers located in France, the United Kingdom and the United States.

  • Revenue in EUR (TTM)3.31bn
  • Net income in EUR617.10m
  • Incorporated1998
  • Employees5.07k
  • Location
    Ipsen SA65 Quai Georges GorseBOULOGNE-BILLANCOURT 92100FranceFRA
  • Phone+33 158335000
  • Fax+33 158335001
  • Websitehttps://www.ipsen.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Hikma Pharmaceuticals Plc2.66bn175.50m4.87bn8.97k27.802.3911.691.830.67650.676510.237.870.62841.763.67253,693.804.208.195.7211.3048.9450.296.6813.770.90297.680.350336.7114.226.731.06-7.597.974.54
Orion Oyj1.19bn216.80m4.87bn3.63k22.285.4418.464.091.551.558.496.340.80881.575.56327,588.1014.7219.4718.0324.1655.3059.3818.2020.711.7594.790.183591.83-11.264.01-37.971.8911.821.55
DiaSorin SpA-100.00bn-100.00bn4.97bn3.28k--------------------------13.14--14.79--67.40--23.33------23.899.9816.38-22.5311.4921.765.29
Grifols SA6.59bn59.31m5.09bn23.74k92.040.96688.180.77230.09010.09019.808.580.30681.239.86277,627.000.84082.391.063.0437.8440.262.747.541.291.560.5593--8.718.00-71.52-36.98-0.8127--
Zealand Pharma A/S45.97m-94.38m5.72bn253.00--24.98--124.49-12.57-12.576.0127.280.19484.16289.881,354,889.00-39.99-42.74-46.30-50.2487.3996.13-205.30-464.666.23--0.0696--229.6555.2727.12--42.53--
BACHEM HOLDING AG589.98m114.31m6.48bn2.01k56.404.8040.3710.981.501.507.7317.610.37651.233.33287,794.607.298.858.1710.2830.6531.6319.3819.743.0429.800.000355.378.5715.3711.1019.1250.887.78
Croda International Plc1.98bn199.62m7.91bn5.85k39.682.8822.724.001.221.2212.1216.850.47132.404.39289,559.104.7910.805.4212.5143.0846.4110.1618.641.7717.070.230743.44-18.904.09-73.66-6.4212.784.11
Swedish Orphan Biovitrum AB (publ)1.93bn209.67m8.40bn1.79k36.792.7317.204.367.407.4068.6599.680.34971.384.25--3.815.935.207.6077.5877.4110.8816.610.46074.040.37690.0017.7419.34-8.68-0.072953.61--
Qiagen NV1.82bn315.26m8.74bn5.97k27.932.4817.314.821.411.418.1215.890.31691.935.38304,232.905.505.416.606.5362.7764.6517.3716.351.62--0.2839---8.235.53-19.3512.381.55--
Ipsen SA3.31bn617.10m9.15bn5.07k14.772.3612.892.777.397.7239.6646.290.5541.995.23--10.489.7113.9313.3382.7282.7618.9116.020.98930.430.110619.874.757.084.039.75-8.653.71
Recordati Industria Chmc Frmctc SpA2.03bn375.37m10.82bn4.37k28.496.1620.785.331.821.829.848.390.4951.574.99465,081.009.1412.8211.5916.3868.7871.0518.4722.480.859911.850.512861.8317.297.55-19.081.5845.876.23
Eurofins Scientific SE6.51bn516.50m11.08bn61.80k22.002.179.781.702.611.3032.9226.440.621336.204.79105,417.605.417.496.709.3620.9323.788.7111.231.388.430.433219.28-2.9411.49-21.5310.918.5811.66
Sandoz Group AG-102.19bn-102.19bn11.71bn23.85k------------------------------------------------7.23---90.92------
BioMerieux SA3.67bn357.60m11.98bn13.84k33.623.1923.323.263.013.0130.8531.760.70361.975.00--6.189.307.8812.3155.9956.518.7812.381.19--0.121519.012.398.70-20.956.878.3619.42
Data as of Mar 28 2024. Currency figures normalised to Ipsen SA's reporting currency: Euro EUR

Institutional shareholders

11.77%Per cent of shares held by top holders
HolderShares% Held
Parvus Asset Management Europe Ltd.as of 27 Apr 20234.24m5.06%
The Vanguard Group, Inc.as of 07 Mar 20241.21m1.45%
Oddo BHF Asset Management SASas of 29 Feb 2024859.68k1.03%
Norges Bank Investment Managementas of 31 Dec 2023857.79k1.02%
BlackRock Fund Advisorsas of 07 Mar 2024801.02k0.96%
BlackRock Advisors (UK) Ltd.as of 07 Mar 2024494.33k0.59%
Black Creek Investment Management, Inc.as of 30 Sep 2023463.57k0.55%
Liontrust Investment Partners LLPas of 31 Jan 2024338.36k0.40%
Dimensional Fund Advisors LPas of 07 Mar 2024307.35k0.37%
Geode Capital Management LLCas of 20 Mar 2024288.77k0.35%
More ▼
Data from 31 Dec 2023 - 01 Mar 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.